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Summary
Background The INTERVAL trial showed that, over a 2-year period, inter-donation intervals for whole blood donation 
can be safely reduced to meet blood shortages. We extended the INTERVAL trial for a further 2 years to evaluate the 
longer-term risks and benefits of varying inter-donation intervals, and to compare routine versus more intensive 
reminders to help donors keep appointments.
Methods The INTERVAL trial was a parallel group, pragmatic, randomised trial that recruited blood donors aged 
18 years or older from 25 static donor centres of NHS Blood and Transplant across England, UK. Here we report on the 
prespecified analyses after 4 years of follow-up. Participants were whole blood donors who agreed to continue trial 
participation on their originally allocated inter-donation intervals (men: 12, 10, and 8 weeks; women: 16, 14, and 
12 weeks). They were further block-randomised (1:1) to routine versus more intensive reminders using computer-
generated random sequences. The prespecified primary outcome was units of blood collected per year analysed in the 
intention-to-treat population. Secondary outcomes related to safety were quality of life, self-reported symptoms 
potentially related to donation, haemoglobin and ferritin concentrations, and deferrals because of low haemoglobin and 
other factors. This trial is registered with ISRCTN, number ISRCTN24760606, and has completed.
Findings Between Oct 19, 2014, and May 3, 2016, 20 757 of the 38 035 invited blood donors (10 843 [58%] men, 9914 [51%] 
women) participated in the extension study. 10 378 (50%) were randomly assigned to routine reminders and 10 379 
(50%) were randomly assigned to more intensive reminders. Median follow-up was 1·1 years (IQR 0·7–1·3). Compared 
with routine reminders, more intensive reminders increased blood collection by a mean of 0·11 units per year (95% CI 
0·04–0·17; p=0·0003) in men and 0·06 units per year (0·01–0·11; p=0·0094) in women. During the extension study, 
each week shorter inter-donation interval increased blood collection by a mean of 0·23 units per year (0·21–0·25) in 
men and 0·14 units per year (0·12–0·15) in women (both p<0·0001). More frequent donation resulted in more 
deferrals for low haemoglobin (odds ratio per week shorter inter-donation interval 1·19 [95% CI 1·15–1·22] in men and 
1·10 [1·06–1·14] in women), and lower mean haemoglobin (difference per week shorter inter-donation interval –0·84 
g/L [95% CI –0·99 to –0·70] in men and –0·45 g/L [–0·59 to –0·31] in women) and ferritin concentrations (percentage 
difference per week shorter inter-donation interval –6·5% [95% CI –7·6 to –5·5] in men and –5·3% [–6·5 to –4·2] in 
women; all p<0·0001). No differences were observed in quality of life, serious adverse events, or self-reported symptoms 
(p>0.0001 for tests of linear trend by inter-donation intervals) other than a higher reported frequency of doctor-
diagnosed low iron concentrations and prescription of iron supplements in men (p<0·0001).
Interpretation During a period of up to 4 years, shorter inter-donation intervals and more intensive reminders resulted 
in more blood being collected without a detectable effect on donors’ mental and physical wellbeing. However, donors 
had decreased haemoglobin concentrations and more self-reported symptoms compared with the initial 2 years of the 
trial. Our findings suggest that blood collection services could safely use shorter donation intervals and more intensive 
reminders to meet shortages, for donors who maintain adequate haemoglobin concentrations and iron stores. 
Funding NHS Blood and Transplant, UK National Institute for Health Research, UK Medical Research Council, and 
British Heart Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
INTERVAL was the first randomised trial, to the best of 
our knowledge, to evaluate the efficiency and safety 
of varying the frequency of whole blood donation.1–3 We 
randomly assigned over 45 000 blood donors recruited 
across England, UK, to different inter-donation intervals 
(8, 10, and 12 weeks for men; and 12, 14, and 16 weeks for 
women) over a period of 2 years with more intensive 
reminders than standard for NHS Blood and Transplant 
(NHSBT). During that time, there was a substantial 
increase in the amount of blood collected by reducing 
the inter-donation intervals combined with intensive 
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reminders to follow up missed appointments without 
detectable effects on overall quality of life, physical 
activity, or cognitive function of the donors.1,4
These results suggested that, over a duration of about 
2 years, blood collection services could safely use 
shorter donation intervals to meet shortages, such as 
during periods of high demand.5 However, the 
INTERVAL trial showed that increased donation 
frequency resulted in a greater number of deferrals 
(temporary suspension of donors from giving blood) 
because of low haemoglobin, lower average haemo-
globin and ferritin concentrations, and more self-
reported symptoms (more self-reported symptoms 
were seen especially among men).1 Hence, it is 
important to assess the acceptability and sustainability 
of varying the frequency of whole blood donation for 
periods longer than 2 years.
We extended the INTERVAL trial for up to a further 
2 years to compare the longer-term effects of donating 
whole blood using standard inter-donation intervals in 
the UK with shorter inter-donation intervals used in other 
countries.6–8 During the extension study, we also 
compared the use of more intensive reminders to keep 
blood donation appointments versus the routine 
reminders used by the NHSBT blood service in England. 
Methods
Study design and participants
INTERVAL was a parallel group, pragmatic, randomised 
trial.1–3 Full details of the INTERVAL trial have been 
published previously.1–3 In brief, eligible donors were 
aged 18 years or older, fulfilled routine criteria for 
donation, had an email address and access to the 
internet to respond to web-based questionnaires, and 
were willing to be randomly assigned to any of the 
trial’s intervention groups at one of the 25 static donor 
centres of NHSBT, the sole blood provider to the NHS 
in England, UK.
In the main trial, men were randomly assigned to 
12-week (standard), 10-week, or 8-week inter-donation 
intervals, and women to 16-week (standard), 14-week, 
or 12-week intervals. Randomisation of donors to sex-
specific intervention groups in the ratio of 1:1:1 was 
done at the coordinating centre using a minimisation 
algorithm to ensure key characteristics (age, weight, and 
numbers of new vs existing donors) were balanced across 
trial groups at baseline. Because of the nature of the 
intervention, it was not possible to mask participants to 
their allocated inter-donation interval intervention group. 
During the main trial, donors were followed up for a 
period of 2 years after randomisation. Routine NHSBT 
blood donation procedures, including eligibility screening 
with the copper sulphate test, were adopted because of 
the pragmatic trial design.
In the extension study reported here, donors nearing 
completion of their 2-year participation in the main trial 
were invited by email to continue donating blood at their 
allocated inter-donation intervals beyond the 2-year 
period initially agreed (appendix p 22–24). Participants 
were assigned to active (ie, more intensive) or routine 
reminders for donation appointments. The active 
reminder system (as used in the main trial) consisted of 
a uniform three-step reminder process of email, text 
message, and telephone call to encourage donation 
attendance, with a particular focus on donors missing 
appointments. The routine reminders followed the 
standard NHSBT protocol, which was less intense 
(appendix p 22–24). 
Research in context
Evidence before this study
We searched for randomised trials published in English from 
database inception to March 1, 2019, investigating the effect of 
intensive approaches to help whole blood donors keep 
appointments, or of varying the inter-donation interval. We 
searched PubMed, Scientific Citation Index Expanded, 
and Embase using relevant terms: “blood donation intervals”, 
“blood donation frequency”, “blood supply”, “donor health”, 
“appointments”, and “reminders”. Regarding trials of approaches 
to remind donors to keep appointments, we could not identify 
any previous relevant studies. Regarding trials of varying the 
inter-donation interval, we identified only the INTERVAL trial, 
a trial of 45 263 donors that showed that, over a two-year period, 
inter-donation intervals for whole blood donation can be safely 
reduced to meet blood shortages. However, longer-term data are 
needed to inform policy more appropriately.
Added value of this study
As probably the first randomised trial of the effects of giving 
blood donors intensive reminders to help keep their 
appointments, the present study should provide unique insight 
into this question. Regarding the longer-term effects of varying 
the inter-donation interval, the present study extended the 
original INTERVAL trial beyond its initial 2-year period for up to 
a further 2-year period, recording a set of comprehensive 
outcomes relating to blood donation, clinical safety, and 
biochemistry.
Implications of all the available evidence
Our results give policy makers in the UK two additional 
evidence-based options to meet blood supply needs, that is, 
the use of frequent reminders to help donors keep 
appointments and shorter inter-donation intervals than are 
now standard. Our data also quantify the extent of iron 
depletion within 4 years of repeated donation, thus informing 
safety guidelines. Finally, our results suggest a need to review 
the screening method used in the UK to test individuals’ 
eligibility to donate.
See Online for appendix
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Donors aged 20 years or older were eligible immediately 
after completion of their 2-year participation in the main 
trial, provided they could contribute at least 6 months of 
follow-up before the end of the main trial follow-up study 
period (ie, June 16, 2016). Participants gave electronic 
informed consent. The National Research Ethics Service 
approved (11/EE/0538) this study.
Randomisation and masking
Participants were block-randomised within each of the 
main trial groups (inter-donation interval, men: 12, 10, and 
8 weeks; women: 16, 14, and 12 weeks) to active (ie, more 
intensive) or routine reminders for donation appointments 
(figure 1). Simple 1:1 randomisation was done by the trial’s 
senior data manager (MW) at the coordinating centre 
Figure 1: Trial profile
CONSORT flowchart showing recruitment, participation, and completeness of main outcomes in the extension study. *Participants who were randomised but later 
withdrew consent for any further use of their data. †Due to staggered roll-out of the main 2-year trial, only participants expected to attend at least two more sessions 
were considered eligible for invitation to the extension study. ‡Participants not consenting to the extension study reverted to routine NHS Blood and Transplant 
reminders (men every 12 weeks, women every 16 weeks). §Number for whom a physical component score could be calculated at the end of the extension trial. 
¶Number who provided a research blood sample at the end of the extension trial from which haemoglobin and ferritin were measured. ||Number who responded to 
at least one question in any of the 6-monthly questionnaires administered during their participation in the extension study.
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using computer-generated random sequences in block 
sizes of six or eight within the main trial groups. As was 
the case in the initial trial period, it was not possible to 
mask participants in the extended study to their allocated 
inter-donation interval group because of the nature of the 
intervention. Participants were not informed of their 
randomly allocated group in the extension study, although 
individuals returning to routine reminders might have 
noticed the change. Donors who did not consent to 
participate in the extension study returned to NHSBT’s 
standard inter-donation intervals (12 weeks for men, 
16 weeks for women) and routine appointment reminders. 
For these participants, consent given at the beginning of 
the main trial allowed retrieval of anonymised data for 
blood donations from NHSBT’s national database. During 
the extension study, only the trial’s senior data manager 
(MW) and study coordinator (CM) knew the allocations to 
active versus routine reminders for purposes of 
coordination. Laboratory technicians were unaware of the 
groups to which participants had been randomised.
Procedures
The extension study used the same procedures as in the 
main trial.1–3 These included online administration of 
6-monthly questionnaires to monitor donor safety 
characteristics, and a final questionnaire and collection 
of a non-fasting research blood sample at the end of the 
study. These blood samples were transported to a central 
laboratory for a full blood count analysis (Sysmex 
XN-2000 haematology analyser, UK BioCentre, Stockport, 
UK). Ferritin concentrations were measured in stored 
serum samples with an immunoturbidimetric assay 
(Roche/Hitachi chemistry analyser, Stichting Huisartsen 
Laboratorium, Etten-Leur, Netherlands). As with the 
main trial, at each attendance, donors underwent routine 
screening for eligibility to donate blood, including pin-
prick haemoglobin screening via a gravimetric method 
(copper sulphate test), followed by the spectrophotometric 
HemoCue test (HemoCue AB, Ängelholm, Sweden) with 
venous blood for individuals who did not pass the copper 
sulphate test (minimum thresholds to donate in England, 
UK, are 135 g/L for men and 125 g/L for women).9
Outcomes
The primary outcome was the number of whole blood 
donations made during the extension study expressed as 
units per year, with standard practice being to donate 
1 unit of blood per session (full donation unit 470 mL). 
The primary outcome was assessed in 20 757 randomly 
assigned participants, by intention-to-treat. Secondary 
outcomes related to safety were deferrals of donors 
(ie, temporary rejection) for low haemoglobin and other 
factors, haemoglobin and ferritin concentrations, quality 
of life (using physical and mental wellbeing scores from 
the Short Form Health Survey, version 210), self-reported 
symptoms potentially related to blood donation (fainting 
or feeling faint, tiredness, breathlessness, palpitations, 
dizziness, chest pain, restless legs, reported low iron 
concentrations, use of iron supplements, pica), cost-
effectiveness of reducing donation intervals (not reported 
here), and other blood cell-related measures at the end of 
the extension study reported as secondary exploratory 
outcomes.
Statistical analysis
The statistical analysis followed a prespecified plan for 
the extension study. The sample size calculation was 
Figure 2: Whole blood donation rate during the main trial and in the extension study by sex and 
inter-donation intervals
All participants in the main trial were allocated to active reminders. Participants not included in the extension 
study automatically reverted to standard inter-donation intervals (12 weeks for men, 16 weeks for women) at their 
completion of the main trial, with anonymised lookup of blood donation information from NHS Blood and 
Transplant records made possible by consent given at the beginning of the main trial. The blood donation rates for 
these participants during the period of the extension study are shown according to the original randomised 
groups, purely for comparison purposes, even though they had all reverted to the standard inter-donation 
intervals. Error bars denote 95% CI. *Allocated to routine reminders in the extension study. †Allocated to active 
reminders in the extension study.
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done for the original trial.1 Data for men and women 
were analysed separately by the intention-to-treat 
principle according to their randomised groups. For 
prespecified subgroup analyses, ferritin values were log 
transformed and presented as geometric means and 
used to classify donors as iron depleted (<15 μg/L) 
according to WHO criteria.11 For all other outcomes, we 
present means and percentages without adjustment. 
Analysis of outcomes by active versus routine reminders 
involved simple differences between groups. For analysis 
of outcomes by main trial inter-donation interval groups, 
linear trend was assessed statistically; any non-linearity 
was identified only graphically. To inform generalisability, 
we assessed differences in baseline characteristics and 
outcomes at the end of the main trial, first between 
individuals who participated in the extension study 
versus individuals who did not, and second across the 
main trial randomised inter-donation groups in 
individuals who took part in the extension study. We 
compared groups by calculating p values for differences 
or linear trend using Poisson regression models for 
rates, normal regression models for continuous 
outcomes, and logistic regression models for binary 
outcomes. To minimise potential bias, we adjusted for 
centre, baseline age, weight, and new donor status, and 
other covariates when relevant. Precision of estimates 
were displayed as 95% CIs. For outcomes derived from 
multiple donation sessions attended, or multiple 
questionnaires answered by each participant, the 
95% CIs were based on robust standard error estimates 
to avoid optimism in the level precision. Because of the 
number of statistical tests done, we used the following 
guidelines for considering whether the results provided 
strong evidence: p<0·005 for the analyses of whole blood 
donation rates (ie, the primary outcome), and p<0·0001 
for other tests. Analyses were done with Stata, version 13.
There were no protocol amendments or deviations 
from the trial protocol. This trial is registered with 
ISRCTN, number ISRCTN24760606, and has completed. 
An independent data monitoring committee periodically 
reviewed summaries of the trial data for safety purposes.
Role of the funding source
The academic investigators and representatives of 
NHSBT, a funder of the trial, participated in the study 
design and oversight. The investigators at the trial’s 
academic coordinating centre had sole access to the trial 
database, and had final responsibility for data collection, 
data integrity, data analysis and interpretation, as well as 
manuscript drafting and the decision to submit the 
manuscript for publication. All authors gave approval to 
submit for publication.
Results
Between Oct 19, 2014, and May 3, 2016, of 
45 042 participants who completed the main trial, 
38 035 (84·4%; 18 754 men, 19 281 women) were invited to 
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participate in the extension study. Of those invited, 
20 757 (54·6%; 10 843 men, 9914 women) consented and 
were randomly assigned to active versus routine 
appointment reminders (figure 1, appendix p 12). The 
percentage of participants invited and those consenting 
were similar across the main trial’s sex-specific 
randomised inter-donation interval groups (figure 1). 
Median follow-up during the extension study was 
1·1 years (IQR 0·7–1·3).
Participants who consented to the extension study 
differed from participants who did not in several 
characteristics recorded at the beginning and during the 
main trial (appendix pp 3–4). Compared with participants 
who did not take part, participants were older (by a mean 
of 7·4 years [95% CI 7·1–7·6]), more committed and 
adherent within the main trial (donating 79% [95% CI 
77–82] more blood), had fewer deferrals, and had a lower 
frequency of self-reported symptoms (appendix p 3–4). 
Donation rates in donors who did not take part in the 
extension study (ie, individuals reverting to standard 
inter-donation intervals at the end of the main trial) were 
lower than in individuals who participated (figure 2).
Information on the primary outcome was available for 
20 717 (99·8%) of 20 757 participants (figure 1). Baseline 
characteristics of participants were well balanced across 
the randomised active versus routine reminders trial 
groups (appendix p 8). Mean whole blood donation rates 
for active versus routine reminders in men were 3·50 
(95% CI 3·45–3·54) versus 3·39 (3·34–3·44) units per 
year, or a mean difference of 0·11 (95% CI 0·04–0·17; 
p=0·00028) units per year (figure 2; appendix pp 9, 13). 
Corresponding results in women were 2·33 (95% CI 
2·30–2·37) versus 2·28 (2·24–2·31) units per year, or 
mean difference of 0·06 units per year (95% CI 0·01–0·11; 
p=0·0094). No significant differences were observed 
between the active and routine reminder groups in 
outcomes related to safety (appendix p 9). The effect of 
active reminders on blood donation rates did not vary 
according to inter-donation intervals (figure 2; interaction 
test p=0·86 in men and p=0·55 in women).
From the 20 757 participants, availability of secondary 
outcomes assessed at the end of the extension study 
varied: 20 717 (99·8%) for deferrals per donation session 
attended; 18 638 (89·8%) for self-reported symptoms; 
16 388 (79·0%) for physical wellbeing score; 15 572 (75·0%) 
for haemoglobin and other blood cell measures; and 
13 681 (65·9%) for ferritin concentration (figure 1). 
Availability of these outcomes was broadly similar between 
randomised groups (appendix p 12).
In the participants included in the extension study, the 
effects of shorter inter-donation intervals during the first 
2 years were consistent with the main trial findings, 
including lower concentrations of haemoglobin and 
ferritin (appendix p 5). Exploratory analyses showed that 
shorter inter-donation intervals also led to lower 
concentrations of other commonly assessed haema-
tological variables at the end of the main trial (appendix 
p 6). In this subset of participants, however, there was no 
evidence of the effects of shorter inter-donation intervals 
on self-reported symptoms (eg, tiredness, feeling faint, 
dizziness, breathlessness), although there was a higher 
reported frequency of doctor-diagnosed low iron concen-
trations and prescription of iron supplements in men 
(both p<0·0001; appendix p 7).
Grade* Overall Men (n=10 843 in extension) Women (n=9914 in extension)
N n (%) 8 weeks 10 weeks 12 weeks 12 weeks 14 weeks 16 weeks
Any self-reported serious adverse events† ·· 18 550 536 (2·9%) 75 (2·4%) 91 (2·8%) 93 (2·9%) 82 (2·7%) 102 (3·5%) 93 (3·2%)
Doctor diagnosed heart problems 3 18 528 69 (0·4%) 14 (0·4%) 20 (0·6%) 17 (0·5%) 4 (0·1%) 5 (0·2%) 9 (0·3%)
Doctor diagnosed heart failure 3 18 528 18 (0·1%) 5 (0·2%) 4 (0·1%) 5 (0·2%) 1 (0·0%) 1 (0·0%) 2 (0·1%)
Doctor diagnosed heart attack 3 18 526 20 (0·1%) 7 (0·2%) 5 (0·2%) 4 (0·1%) 1 (0·0%) 0 (0·0%) 3 (0·1%)
Doctor diagnosed angina 3 18 526 24 (0·1%) 6 (0·2%) 6 (0·2%) 5 (0·2%) 1 (0·0%) 4 (0·1%) 2 (0·1%)
Doctor diagnosed stroke 3 18 527 17 (0·1%) 4 (0·1%) 7 (0·2%) 1 (0·0%) 2 (0·1%) 1 (0·0%) 2 (0·1%)
Doctor diagnosed transient ischaemic attack 3 18 527 21 (0·1%) 5 (0·2%) 5 (0·2%) 5 (0·2%) 2 (0·1%) 1 (0·0%) 3 (0·1%)
Visit to hospital for a fall 3 18 533 337 (1·8%) 39 (1·2%) 39 (1·2%) 47 (1·5%) 64 (2·1%) 81 (2·8%) 67 (2·3%)
Visit to hospital for transport accident 3 18 516 150 (0·8%) 26 (0·8%) 36 (1·1%) 36 (1·1%) 17 (0·6%) 17 (0·6%) 18 (0·6%)
Any symptom self-reported 1–2 18 554 9732 (52·5%) 1581 (49·6%) 1556 (47·1%) 1476 (45·6%) 1764 (58·8%) 1699 (58·0%) 1656 (57·2%)
Fainting or feeling faint 1–2 18 534 2085 (11·3%) 325 (10·2%) 302 (9·2%) 269 (8·3%) 424 (14·1%) 390 (13·3%) 375 (13·0%)
More tired than usual 1–2 18 537 5198 (28·0%) 864 (27·1%) 823 (24·9%) 800 (24·8%) 947 (31·6%) 881 (30·1%) 883 (30·5%)
Palpitations 1–2 18 502 2217 (12·0%) 271 (8·5%) 286 (8·7%) 261 (8·1%) 498 (16·6%) 435 (14·9%) 466 (16·2%)
Dizziness 1–2 18 533 3197 (17·3%) 457 (14·4%) 456 (13·8%) 419 (13·0%) 657 (21·9%) 617 (21·1%) 591 (20·4%)
Restless legs syndrome 1–2 18 464 4158 (22·5%) 642 (20·2%) 642 (19·5%) 613 (19·0%) 776 (26·0%) 753 (25·8%) 732 (25·4%)
Data presented are n (%) unless otherwise stated. Adverse events listed in this table were ascertained only through self-report questionnaires and mapped to Common Terminology Criteria for Adverse Events 
grading using heuristic criteria. For adverse events of grade 1–2, only those occurring in 10% or more of patients are reported. *Grading with reference to Common Terminology Criteria for Adverse Events 
version 5.0. †Number and percentage of participants reporting any serious adverse events during the extension study in any of the 6-monthly questionnaires, including doctor-confirmed heart failure, heart 
attack, angina, stroke, or transient ischaemic attack; or hospital visit for falls or transport accidents. Study participants could contribute to more than one outcome in this table.
Table 2: Adverse events during the extension study by inter-donation interval groups
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Baseline characteristics of participants were broadly 
similar across the inter-donation interval groups 
(appendix p 5). Donors continuing to donate at shorter 
inter-donation intervals gave more blood during the 
extension study than individuals continuing on the 
longer intervals (men an extra 0·23 units per year 
[95% CI 0·21–0·25], women an extra 0·14 units per year 
[0·12–0·15], per week shorter interval based on linear 
trend, both p<0·0001; figure 3, table 1). There were no 
clear differences across trial groups in physical and 
mental wellbeing scores or reported frequency of self-
reported symptoms other than a higher reported 
frequency of doctor diagnosed low iron concentrations 
and prescription of iron supplements in men (table 1; 
appendix pp 10, 14). Similarly, there were no differences 
across trial groups in the frequency of serious adverse 
events (eg, heart failure, myocardial infarction, stroke, 
falls, or transport accidents; table 2). However, donors 
allocated to shorter inter-donation intervals had more 
deferrals for low haemoglobin (odds ratio per week 
shorter inter-donation interval 1·19 [95% CI 1·15–1·22] 
in men and 1·10 [1·06–1·14] in women), and had lower 
mean haemoglobin (difference per week shorter inter-
donation interval –0·84 g/L [95% CI –0·99 to –0·70] in 
men and –0·45 g/L [–0·59 to –0·31] in women) and 
ferritin concentrations (percentage difference per week 
shorter inter-donation interval –6·5% [95% CI –7·6 to 
–5·5] in men and –5·3% [–6·5 to –4·2] in women) at the 
end of the extension study (all p<0·0001; table 1, figure 4; 
appendix p 15). Shorter inter-donation intervals also led 
to lower concentrations of other commonly assessed 
haematological variables at the end of the extension 
study (appendix p 11). The proportion of individuals 
donating blood with haemo globin concentrations less 
than the minimum regulatory threshold and individuals 
with ferritin less than 15 µg/L was higher in donors 
allocated to shorter intervals than in individuals allocated 
to the standard donation intervals (appendix p 16).
During the extension study, blood donation rates in 
each trial group were 14·6% (95% CI 13·1–14·2) lower 
than during the main trial (figure 3). In comparison with 
the main trial, frequency of self-reported symptoms and 
rates of deferral for low haemoglobin increased further 
(appendix pp 14–15), while mean haemoglobin concen-
trations decreased further (figure 4A), especially in men. 
By contrast, mean ferritin concentrations increased 
somewhat, especially in women (figure 4B). Corres-
ponding changes in other haematological variables 
(appendix p 17) showed similar results to haemoglobin 
for some traits (eg, lower mean corpuscular haemoglobin 
and mean corpuscular haemoglobin concen tration) and 
similar to ferritin for other traits (eg, higher mean 
haematocrit, mean corpuscular volume, and reticulocyte 
haemoglobin equivalent). There was no evidence that 
laboratory machine drift or technical errors, as judged by 
evaluation of internal quality control samples, could 
explain differences in the above-mentioned variables.
The proportion of donors who reported that their 
doctor had prescribed iron supplements increased 
through the duration of the INTERVAL trial up to 4·0% 
(95% CI 3·7–4·4) by the end of the extension study, and 
together with individuals reporting the use of over-the-
counter iron supplements, comprised 1396 (16%) of 
8594 men and 1732 (22%) of 7803 women by the end of 
the extension study, with higher proportions in donors 
allocated to shorter intervals (appendix p 18).
In post-hoc analyses, which stratified comparisons 
according to patterns of reported use of any iron 
supplements during the main trial or extension study, 
the decrease in mean haemoglobin concentrations was 
larger (appendix p 19) and the increase in mean ferritin 
concentrations no longer apparent (appendix p 20) 
among the participants who did not report using iron 
supplements throughout the trial. Similarly, stratified 
post-hoc results for reticulocyte haemoglobin concen-
tration (appendix p 21) showed increased concentrations 
during the extension study even in the subgroup of 
participants who were iron supplement-naive.
Figure 4: Haemoglobin (A) and ferritin (B) concentrations at the end of the extension study, end of the main 
trial period, and at baseline by sex and inter-donation intervals
Analysis is restricted to participants in the extension study. The p values assess trends across inter-donation 
intervals, adjusted for baseline characteristics (centre, age, weight, new donor status, and haemoglobin [A] or loge 
ferritin [B]). Error bars denote 95% CI.
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Discussion
This trial extended the intervention and follow-up 
periods of INTERVAL, a randomised trial of varying 
inter-donation intervals in whole blood donors. We also 
did a randomised comparison of different approaches to 
remind donors to keep blood donation appointments. 
This extension study’s main result was that, over a 
period of 2–4 years, shorter inter-donation intervals and 
more intensive reminders resulted in more blood being 
collected.
Our trial was notable because it quantified key 
measures that blood services aim to balance in 
maintaining the blood supply while safeguarding the 
health of donors. Our extension study showed that, 
beyond a 2-year period, each week reduction in time 
between donations led to an increase of 0·23 units in the 
amount of blood collected per year in men and of 
0·14 units in women compared with the donation 
intervals currently used in the UK (ie, 12 weeks in men 
and 16 weeks in women).6 With regard to use of more 
intensive approaches to remind donors of appointments, 
our study showed a mean increase of 0·11 units of blood 
per year in men and of 0·06 units of blood per year in 
women. These modest increases due to additional 
reminders could potentially translate to collection of an 
approximate extra 75 000 units of blood from a donor base 
of 900 000 with about 47% of men and 53% of women (ie, 
the approximate size of the current donor base in England, 
UK). If more intensive reminders (eg, a telephone call 
when an appointment is missed) could be done at little 
additional cost, then the gain in the amount of blood 
collected could be worthwhile, at least for priority blood 
groups.12–14 The cost implications of a range of alternative 
policies to encourage blood donation, partly based on the 
INTERVAL trial, have been published elsewhere.15
Regarding safety, the trial showed that reducing inter-
donation intervals during the extension study did not 
have major adverse effects on self-reported mental and 
physical wellbeing, specific symptoms potentially related 
to blood donation, or in other major adverse events we 
recorded. These results extend those from the main trial 
showing that reducing inter-donation intervals did not 
result in major adverse events or impaired wellbeing.1,8 
However, when compared with the initial 2 years of the 
trial, the proportion of donors reporting specific 
symptoms increased during the extension study, 
suggesting a potential cumulative effect over a longer 
period of time.
Use of shorter donation intervals during the extension 
study also resulted in changes in biomarkers of iron 
homoeostasis, resulting in more deferrals for low 
haemoglobin, decreased mean haemoglobin and serum 
ferritin concentrations, and changes in other red blood 
cell parameters suggesting lower iron availability and 
lower incorporation into red blood cells.16 As observed for 
the main trial, there were modest absolute decreases in 
mean haemoglobin concentrations and other red blood 
cell parameters at the end of the extension study. By 
contrast, proportional reductions were larger for serum 
ferritin, with up to 21% of men and 25% of women with 
serum ferritin concentrations less than 15 g/L at the end 
of the extension study. These results are consistent with 
previous observational studies, suggesting that shorter 
inter-donation intervals are associated with sustained 
and progressively lower iron availability.17,18 However, 
although shorter donation intervals resulted in further 
decreases in haemoglobin levels in the extension study, 
serum ferritin concentrations actually increased some-
what (in parallel with increases in the haemoglobin 
concentration of reticulocytes). Exploratory analyses 
suggest that this result could be explained by the higher 
proportion of donors who reported using iron 
supplements,19,20 as by the end of the extension study 16% 
of men and 22% of women had either been prescribed 
iron supplements, or reported taking over-the-counter 
iron supplements.21,22
Our findings could have several potential implications 
for blood donation practice and policy. First, our results 
provide evidence for the long-term safety of more 
frequent donation and give policy makers in the UK the 
option to allow more frequent collection from donors 
than is now standard.6 Nevertheless, total reliance on this 
strategy might make a blood service overly dependent on 
a subgroup of donors who are the most resilient to iron 
depletion, either biologically or through iron supple-
mentation.23 Another option would be to use shorter 
inter-donation intervals only for more resilient donors, if 
such donors could be identified in advance by 
demographic, haematological, or genetic characteristics.1
Second, our data provide convincing evidence of the 
cumulative effect on haemoglobin concentrations and 
iron stores of donating blood frequently, which should 
inform safety guidelines for blood services that allow 
more frequent donation than in the UK (eg, USA, France, 
and Germany). Our results support the recent changes in 
the Canadian Blood Services that have increased the 
minimum inter-donation interval in women to reduce 
iron deficiency and deferrals for low haemoglobin.24
Third, given the decrease in haemoglobin concen-
trations we observed over a longer period, it is essential 
for blood services to protect the health of donors by 
adopting appropriate screening methods to test donors’ 
eligibility to donate whole blood.25 To evaluate the relative 
merits of different screening methods in the context of 
NHSBT, the COMPARE study (ISRCTN90871183) aims 
to provide a systematic, within-person comparison of 
different methods to measure haemoglobin concen-
trations in whole blood donors to inform approaches for 
routine eligibility checks in England, UK. Furthermore, 
other blood services have implemented or are evaluating 
additional approaches to detect iron deficiency, such as 
ferritin monitoring in selected blood donors.22,26
Fourth, our findings underscore the potential benefits 
of effective communication with blood donors to 
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encourage attendance, especially in an appointments-
based system such as used by NHSBT in England, UK.
Our study had strengths. Because we evaluated the 
long-term safety and efficiency of frequent donation 
beyond a 2-year period in a randomised study, our trial 
provides more reliable insights than do observational 
studies, which are susceptible to confounding. The trial 
recorded a comprehensive set of outcomes relating to 
blood donation, clinical safety, and biochemistry, and 
provided almost complete outcome data for amount 
of blood collected and deferrals because of low 
haemoglobin.
The study also had limitations. Continuation into the 
extension study was accepted by 55% of those invited, 
and therefore analyses are less powerful than in the main 
trial. Although the participants in the main trial were 
broadly representative of the national donor population 
in England, UK, individuals in the extension study were 
an older and more committed subset of blood donors; 
they had also had fewer deferrals for low haemoglobin 
and reported fewer symptoms. Hence, caution is needed 
in extrapolating the findings to the general population of 
blood donors. For example, more intensive reminders 
could yield even more blood donations in less selected 
groups than our enthusiastic donors who decided to 
enrol in the extension study (who tend to miss few 
opportunities to give blood anyway).27,28 
During the extension study, half of the participants 
were switched from active to routine reminders, a switch 
which could explain a small part of why blood donation 
during the extension study decreased by about 15% 
compared with the initial 2 years of the trial. However, 
drivers of the decreased donation rate between the main 
trial and the extension study could not be established 
given the study design.29 Although participants were not 
informed of their randomly allocated group in the 
extension study, individuals returning to routine 
reminders might have noticed the change and potentially 
be influenced by the active reminders from the main trial. 
The study relied on self-reported information for some 
outcomes (eg, symptoms), which might be susceptible to 
reporting biases and incompleteness (ie, missing data). 
We did not have accurate information from the 6-monthly 
question naires about the timing of reported iron 
supplement use, and therefore could not distinguish 
whether it might be related to previous deferral or sub-
sequent donation.
In summary, during a period of 2–4 years, collection of 
substantially more blood without a detectable effect on 
donors’ mental and physical wellbeing was achieved 
through more frequent donation than is standard 
practice in the UK and more intensive reminders to keep 
blood donation appointments. However, compared with 
the initial 2 years of the trial, extension of this approach 
resulted in further lowering of haemoglobin concen-
trations, more deferrals, and higher rates of self-reported 
symptoms.
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